Lifecore Biomedical
LFCR
91 hedge funds and large institutions have $323M invested in Lifecore Biomedical in 2019 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 31 increasing their positions, 28 reducing their positions, and 8 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
11% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 28
6% more capital invested
Capital invested by funds: $306M → $323M (+$17M)
2% more funds holding
Funds holding: 89 → 91 (+2)
2.84% less ownership
Funds ownership: 93.14% → 90.3% (-2.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WC
Walthausen & Co
Malta,
New York
|
+$4.25M |
| 2 |
PCM
Penn Capital Management
Philadelphia,
Pennsylvania
|
+$3.31M |
| 3 |
Russell Investments Group
London,
United Kingdom
|
+$2.61M |
| 4 |
AC
AltraVue Capital
Bellevue,
Washington
|
+$1.67M |
| 5 |
LCM
Legato Capital Management
San Francisco,
California
|
+$1.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Royce & Associates
New York
|
-$6.3M |
| 2 |
NC
Northpointe Capital
Bloomfield Hills,
Michigan
|
-$2.6M |
| 3 |
BlackRock
New York
|
-$1.88M |
| 4 |
Morgan Stanley
New York
|
-$1.09M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$980K |
LFCR Hedge Fund Activity: Q1 2019 in Review
91 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q1 2019, worth a combined $323M — up 5.5% from $306M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new LFCR positions and 8 closed out — a net gain of 2 holders — while 31 added to existing stakes and 28 trimmed.
The largest buyer was Walthausen & Co, adding an estimated $4.25M. The largest seller was Royce & Associates, cutting an estimated $6.3M.
- 91 institutional investors held Lifecore Biomedical (LFCR) as of Q1 2019, up from 89 in Q4 2018.
- Funds reported $323M of Lifecore Biomedical stock for Q1 2019, up 5.5% quarter-over-quarter.
- 10 funds opened new Lifecore Biomedical positions in Q1 2019 and 8 closed out, a net change of +2 holders.
- The largest Lifecore Biomedical buyer in Q1 2019 was Walthausen & Co, an estimated $4.25M added.
- The largest Lifecore Biomedical seller in Q1 2019 was Royce & Associates, an estimated $6.3M sold.
Based on aggregated 13F filings for Q1 2019.